NICE accepts golimumab in rheumatoid arthritis

NICE has recommended golimumab (Simponi), in combination with methotrexate, as another option for the treatment of active rheumatoid arthritis. Like other tumour necrosis factor (TNF) inhibitors, it can be considered for use in patients with:

  • a disease activity score greater than 5.1 on two separate occasions at least 1 month apart, who have undergone trials of two conventional DMARDs, including methotrexate (unless contraindicated), or
  • severe rheumatoid arthritis, who have inadequately responded to other DMARDs, including at least one TNF inhibitor, and for whom rituximab is inappropriate.

NICE approval of golimumab is contingent on the manufacturer supplying the 100mg dose, which should be considered for use in patients >100kg, at the same price as the 50mg dose.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Stop withdrawal of bipolar disorder treatment, health secretary urged

Stop withdrawal of bipolar disorder treatment, health secretary urged

GPs, pharmacists, psychiatrists and patients are calling...

Contraception advice incentive for GPs linked to 'profound' reduction in abortions

Contraception advice incentive for GPs linked to 'profound' reduction in abortions

A scheme offering GPs financial incentives to provide...